1. Badamaev V, Majeed M, Passwater R. Selenium: a quest for better understanding. Altern Ther Health Med. 1996;2(4):59-67.

2. Bernhard MC, Junker E, Hettinger A, et al. Time course of total cysteine, glutathione, and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol. 1998;28(5):751-755.

3. Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol. 2002;36(6):805-811.

4. Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol. 1996;25(5):677-683

5. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology. 1998;27(6):1463-6.

6. Bustamante J, Lodge JK, Marcocci L, et al. Alpha-lipoic acid in liver metabolism and disease. Free Rad Biol Med. 1998;24(6):1023-1039.

7. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997;29(3):315-331.

8. Zeigler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant a-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425-1433.

9. Ibid, ref 6

10. Shabert J, Winslow C, Lacey JM, Wilmore DW. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999;15(11-12):860-864.

11. Herzenberg L, DeRosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Nat Acad Sci USA. 1997;94(5):1967-1972.

12. Beloqui O, Prieto J, Suarez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 1993;13(4):279-82.

13. Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol. 1999;11(11);1203-1207.

14. Ibid, ref 2

15. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res. 1999;43(2):113-122.

16. Garland M, Stamper MJ, Willett WC, Hunter DJ. The epidemiology of selenium and human cancer. In: Balz Grei, Balz Frei (Eds.). Natural Antioxidants in Human Health and Disease. Academic Press. San Diego, California. 1994:263-281.

17. Yu MW, Horng IS, Hsu KH, et al. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J Epidemiol. 1999;150(4):367-374.

18. Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res. 1997;56(1):117-124.

19. Look MP, Rockstroh JK, Rao GS, et al. Serum selenium, plasma glutathione (GSH), and erythrocyte glutathione peroxidase (GSH-Px) levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1) infection. Eur J Clin Nutr. 1997;51(4):266-272.

20. Baum MK, Shor-Posner G, Lai S, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(5):370-374.

21. Osman E, Owen JS, Burroughs AK. Review article: S-adenosyl-L-methionine- a new therapeutic agent in liver disease? Aliment Pharmacol Ther. 1993;7:21-28.

22. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multi-center clinical trial. J Hepatol. 1999;30(6):1081-1089.

23. Ansorena E, Garcia-Trevijano E, Martinez-Chantar M, et al. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology. 2002;35(2):274-280.

24. Podymova SD, Nadinskaia MI. Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome. Klin Med (Mosk). 1998;76(10):45-48.

25. Gorbakov VV, Galik VP, Kirillov SM. Experience in heptral treatment of diffuse liver diseases. Ter Arkh. 1998;70(10):82-86.

26. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized , double-blind, placebo-controlled study. Free Radic Res. 1997;27(6):599-605.

27. Houglum K Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1977;113(4):1069-1073.

28. Chojkier M, Houglum K, Lee KS, Buck M. Long- and short-term D-a-tocopherol supplementation inhibits liver collagen a1(I) gene expression. Am J Physiol. 1998;275(6 Pt 1):G1480-1485.

29. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490.

30. Takagi H, Nagamine T, Abe H, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepatitis. 2001;8(5):367-371.

31. Nagamine T, Takagi H, Takayama H, et al. Preliminary study of combination therapy with IFNa and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Element Res. 2000;75(1-3):53-63.

32. Nagamine T, Takagi H, Takayama H, et al. Preliminary study of combination therapy with IFNa and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Element Res. 2000;75(1-3):53-63.

33. Berkson B. A triple antioxidant approach to the treatment of hepatitis C using alpha-lipoic acid (thioctic acid), silymarin, selenium and other fundamental nutraceuticals. Clin Prac Alt Med. 2000;1(1):27-33.